Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Our 10 medical programs are spread across eight hospital sites – Princess Margaret, Toronto General, Toronto Rehab’s five sites, Toronto Western – as well as our education programs through the Michener Institute of Education at UHN. Learn more about the services, programs and amenities offered at each location.
Maps & Directions
Find out how to get to and around our nine locations — floor plans, parking, public transit, accessibility services, and shuttle information.
Ways You Can Help
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It’s also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
Researchers from UHN have developed and validated an innovative deep learning model to predict a patient's long-term outcome after receiving a liver transplant.
First of its kind in the field of Transplantation, this model is the result of a collaboration between the Ajmera Transplant Centre and Peter Munk Cardiac Centre (PMCC). The study, published in
Lancet Digital Health, shows it can significantly improve long-term survival and quality of life for liver transplant recipients.
"Historically, we have seen good advances in one-year post-transplant outcomes, but survival in the longer term hasn't significantly improved in the past decades," explains Dr. Mamatha Bhat, a hepatologist with the Ajmera Transplant Centre at UHN, and co-senior author of the study.
"This model can guide physicians and help anticipate when and how complications may rise. It can really be paradigm-changing in how we support liver transplant recipients in personalizing their care and helping them live better and longer."
For liver transplant recipients, long-term survival beyond one-year is significantly compromised by an increased risk of cancer, cardiovascular mortality, infection and graft failure. Clinical tools to identify patients at risk of these complications are limited.
More than 80 per cent accurate
This model will help clinicians enhance post-liver transplant care using machine learning, allowing them to identify potential risks when formulating patient-specific treatment plans.
The study results show this model is more than 80 per cent accurate in predicting potential complications for liver transplant recipients at any point post-transplantation, based on their medical history and comparing to the millions of data points compiled using artificial intelligence (AI).
"Deep learning enables timely processing of large-scale datasets, finding patterns and signals that can aid clinicians in better predicting the clinical outcomes and creating specific treatment recommendations," says Dr. Bo Wang, AI Lead at the PMCC, and co-senior author of this study.
The algorithms for this model were created based on the Scientific Registry of Transplant Recipients (SRTR) – a national medical database in the United States, with data from more than 42,000 liver transplant recipients. They were then validated using the local dataset from UHN's Ajmera Transplant Centre, which had over 3,200 cases.
The research team now plans to share this model with clinicians so that it can be used across the world. Work is also in progress to evaluate what are the best formats to streamline its use, either developing a software or mobile application.
This study was supported by the Canadian Liver Foundation, American Society of Transplantation, Canadian Donation and Transplant Research Program, the CIFAR AI Chair Program and the UHN Foundation. Some of the authors are supported by Peter Munk Cardiac Centre AI Fund.